Last reviewed · How we verify

Alfentanil Hydrochloride Injection — Competitive Intelligence Brief

Alfentanil Hydrochloride Injection (Alfentanil Hydrochloride Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist. Area: Anesthesia and Pain Management.

marketed Opioid agonist Mu (μ) opioid receptor Anesthesia and Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Alfentanil Hydrochloride Injection (Alfentanil Hydrochloride Injection) — The First Affiliated Hospital of Xinxiang Medical College. Alfentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Alfentanil Hydrochloride Injection TARGET Alfentanil Hydrochloride Injection The First Affiliated Hospital of Xinxiang Medical College marketed Opioid agonist Mu (μ) opioid receptor
BENZHYDROCODONE BENZHYDROCODONE marketed Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways 2018-01-01
Nucynta TAPENTADOL Collegium Pharm Inc marketed Opioid Agonist Mu-type opioid receptor 2008-01-01
Alfenta ALFENTANIL Rising marketed Opioid Agonist Mu-type opioid receptor 1986-01-01
Dilaudid-Hp Hydromorphone Hydrochloride Fresenius Kabi marketed Opioid agonist Mu-opioid receptor 1984-01-01
Sufenta Preservative Free SUFENTANIL Rising marketed Opioid Agonist Mu-type opioid receptor 1984-01-01
Dilaudid-Hp HYDROMORPHONE Fresenius Kabi marketed Opioid Agonist mu-opioid receptor 1984-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist class)

  1. University of British Columbia · 3 drugs in this class
  2. Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
  3. Kaohsiung Veterans General Hospital. · 2 drugs in this class
  4. Nycomed · 2 drugs in this class
  5. Rigshospitalet, Denmark · 2 drugs in this class
  6. University Hospital, Ghent · 2 drugs in this class
  7. Fundación Universitaria de Ciencias de la Salud · 2 drugs in this class
  8. Erasme University Hospital · 2 drugs in this class
  9. Cephalon · 2 drugs in this class
  10. Corporacion Parc Tauli · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alfentanil Hydrochloride Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/alfentanil-hydrochloride-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: